Companies/Endonovo Therapeutics, Inc.

Company profile

Endonovo Therapeutics, Inc.

OTC: ENDV · Healthcare · Biotechnology

PublicHQ Woodland Hills, CACIK 0001528172Reports USD

#1011 of 1,394 Healthcare companies by revenuetop-quartile growth

EA Score

——

FH —DQ 44GM —SS 26

v0.1 · 25/100 weight · pillars only

↑ revenue growth (YoY), disclosure history · ↓ workforce scale, Altman-Z

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

-$18.5M

Employees

Market cap

$31.9k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$135.4k$135.4k2022

Net income-$18.5M-$18.5M2022

Operating income-$3.3M-$3.3M2022

Total assets$1.3M$1.3M2022

Liabilities$33.5M$33.5M2022

Equity-$32.2M-$32.2M2022

Revenue trend

FY2014 – FY2022 · USD

$22.9k

FY14

$24.2k

FY14

$4.3k

FY15

$83.3k

FY18

$310.2k

FY19

$165.8k

FY20

$73.1k

FY21

$135.4k

FY22

Revenue by segment

Filed disclosures · FY2022

By product

Royalty84%

Direct Sales Medical Care Providers Gross16%

By geography

Not disclosed.

The read

Endonovo Therapeutics, Inc. booked $135.4k in FY2022 revenue, growing 85% year over year — faster than most Healthcare companies we track, at a -13649.2% net margin.

Peers · Healthcare

Medical Imaging Corp.——Health Advance Inc.——LifePoint, Inc.——Next Generation Management Corp.——

Key facts

CEOAlan Brian Collier

SectorHealthcare

IndustryBiotechnology

HeadquartersWoodland Hills, CA

ExchangeOTC: ENDV

Employees1

IPO date2012-11-15

Latest filings

8-K2024-01-03 10-Q2023-12-29 8-K2023-12-04 8-K2023-10-12 10-Q2023-08-21 10-Q2023-05-22 10-K2023-04-17 8-K2023-03-29

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.